BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
Public ClinicalTrials.gov record NCT00727506. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Trial of BIBW 2992 (Afatinib) in Treating Patients With Recurrent Glioblastoma Multiforme
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase I Part: To determine the maximum tolerated dose (MTD) and pharmacokinetics of BIBW 2992 administered in combination with TMZ in patients with recurrent malignant gliomas (WHO Grade III and IV). Phase II Part: To estimate the efficacy and safety of BIBW 2992 monotherapy and BIBW 2992 / TMZ combination therapy compared to TMZ monotherapy (three treatment arms) in patients with recurrent GBM. To evaluate molecular determinants of response to BIBW 2992.
Study identification
- NCT ID
- NCT00727506
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 151 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2008 (Actual)
- Primary completion
- May 12, 2011 (Actual)
- Completion
- May 25, 2016 (Actual)
- Last update posted
- Aug 15, 2017
2008 – 2016
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1200.36.0016 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1200.36.0012 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1200.36.0005 Boehringer Ingelheim Investigational Site | Duarte | California | — | — |
| 1200.36.0014 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1200.36.0019 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 1200.36.0023 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 1200.36.0008 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 1200.36.0002 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 1200.36.0003 Boehringer Ingelheim Investigational Site | Detroit | Michigan | — | — |
| 1200.36.0009 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1200.36.0001 Boehringer Ingelheim Investigational Site | Durham | North Carolina | — | — |
| 1200.36.0007 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1200.36.0020 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | — | — |
| 1200.36.0017 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1200.36.0010 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1200.36.0011 Boehringer Ingelheim Investigational Site | Charlottesville | Virginia | — | — |
| 1200.36.0022 Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00727506, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 15, 2017 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00727506 live on ClinicalTrials.gov.